Dr Reddy’s Share Price in Focus After Collaboration with Immutep on Oncology Drug Eftilagimod Alfa

Dr Reddy’s Laboratories has entered into a strategic collaboration with Immutep to develop and commercialise the oncology drug Eftilagimod Alfa in select global markets. This partnership aims to enhance cancer treatment options worldwide. 

Details of the Collaboration 

On December 8, 2025, Dr Reddy’s Laboratories SA, a subsidiary of Dr Reddy’s Laboratories Limited, signed an exclusive licensing agreement with Immutep SAS, a subsidiary of Immutep Limited.  

This agreement grants Dr Reddy’s the rights to develop and commercialise Eftilagimod Alfa in countries outside North America, Europe, Japan, and Greater China. 

Under the terms, Immutep will receive an upfront payment of $20 million (~AUD 30.2 million) and is eligible for potential milestone payments up to $349.5 million (~AUD 528.4 million), along with double-digit royalties on commercial sales. 

Significance of Eftilagimod Alfa 

Eftilagimod Alfa, or efti, is a first-in-class immunotherapy designed to activate the immune system against cancer. It is currently undergoing Phase III trials for non-small cell lung cancer and is being explored for other cancers like head and neck, breast, and soft tissue sarcoma. 

Read More: Sun Pharma Share Price in Focus; Approves ₹3,000 Crore Greenfield Manufacturing Facility! 

Terms and Conditions of the Agreement 

The agreement allows Dr Reddy’s to develop, register, and commercialise Eftilagimod Alfa in the specified regions, with the right to grant sublicenses. Immutep retains manufacturing rights globally and will supply the product to Dr Reddy’s. 

Dr Reddy's Laboratories Share Price Performance  

As of December 08, 2025, at 3:17 PM, Dr Reddy's Laboratories share price on NSE was trading at ₹1,266.10 down by 0.71% from the previous closing price. 

Conclusion 

The collaboration between Dr Reddy’s and Immutep on Eftilagimod Alfa marks a significant step in expanding access to innovative cancer treatments. The agreement highlights both companies' strategic focus on advancing oncology therapeutics globally. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.